JP2024515968A5 - - Google Patents

Info

Publication number
JP2024515968A5
JP2024515968A5 JP2023565628A JP2023565628A JP2024515968A5 JP 2024515968 A5 JP2024515968 A5 JP 2024515968A5 JP 2023565628 A JP2023565628 A JP 2023565628A JP 2023565628 A JP2023565628 A JP 2023565628A JP 2024515968 A5 JP2024515968 A5 JP 2024515968A5
Authority
JP
Japan
Prior art keywords
antibody
sequence
seq
antibody drug
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565628A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515968A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026005 external-priority patent/WO2022231978A1/en
Publication of JP2024515968A publication Critical patent/JP2024515968A/ja
Publication of JP2024515968A5 publication Critical patent/JP2024515968A5/ja
Pending legal-status Critical Current

Links

JP2023565628A 2021-04-26 2022-04-22 抗gal3抗体製剤およびその使用法 Pending JP2024515968A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163179879P 2021-04-26 2021-04-26
US63/179,879 2021-04-26
PCT/US2022/026005 WO2022231978A1 (en) 2021-04-26 2022-04-22 Anti-gal3 antibody formulations and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024515968A JP2024515968A (ja) 2024-04-11
JP2024515968A5 true JP2024515968A5 (enExample) 2025-04-28

Family

ID=83848624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565628A Pending JP2024515968A (ja) 2021-04-26 2022-04-22 抗gal3抗体製剤およびその使用法

Country Status (5)

Country Link
US (1) US20240158512A1 (enExample)
EP (1) EP4329804A4 (enExample)
JP (1) JP2024515968A (enExample)
CN (1) CN117561080A (enExample)
WO (1) WO2022231978A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2025064944A1 (en) * 2023-09-20 2025-03-27 Vor Biopharma Inc. Anti-cd45 antibody-drug conjugate pharmaceutical compositions
WO2025185724A1 (en) * 2024-03-08 2025-09-12 Sunmed Therapeutic Limited Anti-galectin 3 antibodies and their use in epilepsy and related diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP7382232B2 (ja) * 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗lag3抗体の製剤および抗lag3抗体と抗pd-1抗体との共製剤
WO2020160156A2 (en) * 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) * 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Similar Documents

Publication Publication Date Title
JP2024515968A5 (enExample)
CN111315411B (zh) 高浓度抗c5抗体制剂
TWI806150B (zh) 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
JP4890537B2 (ja) 安定化抗b型肝炎ウイルス(hbv)抗体製剤
JP2022532927A5 (enExample)
IL268202B2 (en) Anti-rsv monoclonal antibody formulation
JP2024544523A5 (enExample)
JP2022036932A5 (enExample)
JP2008528638A5 (enExample)
JP2024531151A5 (enExample)
TW201806617A (zh) 穩定之液體醫藥調配物
JP2023540025A5 (enExample)
CN110382001A (zh) 化脓性汗腺炎的治疗
JP2019532970A5 (enExample)
JP2024540226A5 (enExample)
WO2005072772A1 (en) Pharmaceutical compositions
RU2020111574A (ru) Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом
JP2023502398A5 (enExample)
CN117159703A (zh) 含抗lag-3抗体的药物组合物及其用途
JP2024538140A5 (enExample)
JP2022519796A (ja) 抗pcsk9抗体を含む安定製剤
JP2022519796A5 (enExample)
TW202124454A (zh) 抗pcsk9抗體用於預防或治療膽固醇相關疾病的方法
CN111683681A (zh) 包含抗ox40抗体的制剂、其制备方法及其用途
TW202206457A (zh) 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體